The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Clinical trial NCT04949191 · TERMINATED
Trial details
- NCT number
- NCT04949191
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-08
- Primary completion
- 2024-04-11
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.